PL2981822T3 - Kompozycje i sposoby modulacji czynnika wzrostu - Google Patents

Kompozycje i sposoby modulacji czynnika wzrostu

Info

Publication number
PL2981822T3
PL2981822T3 PL14795041T PL14795041T PL2981822T3 PL 2981822 T3 PL2981822 T3 PL 2981822T3 PL 14795041 T PL14795041 T PL 14795041T PL 14795041 T PL14795041 T PL 14795041T PL 2981822 T3 PL2981822 T3 PL 2981822T3
Authority
PL
Poland
Prior art keywords
modulation
compositions
methods
growth factor
growth
Prior art date
Application number
PL14795041T
Other languages
English (en)
Other versions
PL2981822T4 (pl
Inventor
Thomas SCHURPF
Nagesh K. Mahanthappa
Michelle Marie STRAUB
Original Assignee
Scholar Rock, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51867850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2981822(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scholar Rock, Inc. filed Critical Scholar Rock, Inc.
Publication of PL2981822T4 publication Critical patent/PL2981822T4/pl
Publication of PL2981822T3 publication Critical patent/PL2981822T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
PL14795041T 2013-05-06 2014-05-06 Kompozycje i sposoby modulacji czynnika wzrostu PL2981822T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361819840P 2013-05-06 2013-05-06
US201361823552P 2013-05-15 2013-05-15
US201361900438P 2013-11-06 2013-11-06
EP14795041.4A EP2981822B1 (en) 2013-05-06 2014-05-06 Compositions and methods for growth factor modulation
PCT/US2014/036933 WO2014182676A2 (en) 2013-05-06 2014-05-06 Compositions and methods for growth factor modulation

Publications (2)

Publication Number Publication Date
PL2981822T4 PL2981822T4 (pl) 2021-07-12
PL2981822T3 true PL2981822T3 (pl) 2021-07-12

Family

ID=51867850

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14795041T PL2981822T3 (pl) 2013-05-06 2014-05-06 Kompozycje i sposoby modulacji czynnika wzrostu

Country Status (19)

Country Link
US (13) US9573995B2 (pl)
EP (2) EP2981822B1 (pl)
JP (6) JP2016521283A (pl)
AU (5) AU2014262843B2 (pl)
CA (1) CA2911514A1 (pl)
CY (1) CY1123907T1 (pl)
DK (1) DK2981822T3 (pl)
ES (1) ES2837042T3 (pl)
HR (1) HRP20201914T1 (pl)
HU (1) HUE052232T2 (pl)
IL (4) IL301607B2 (pl)
LT (1) LT2981822T (pl)
PL (1) PL2981822T3 (pl)
PT (1) PT2981822T (pl)
RS (1) RS61778B1 (pl)
SG (3) SG10201913751RA (pl)
SI (1) SI2981822T1 (pl)
SM (1) SMT202100008T1 (pl)
WO (1) WO2014182676A2 (pl)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101282687B (zh) 2005-10-14 2011-11-16 应用研究联盟新西兰有限公司 监测表面特征的方法和装置
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN103328632A (zh) 2010-11-30 2013-09-25 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
US9179844B2 (en) 2011-11-28 2015-11-10 Aranz Healthcare Limited Handheld skin measuring or monitoring device
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
WO2014030728A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 FcγRIIb特異的Fc領域改変体
CN113621057A (zh) 2013-04-02 2021-11-09 中外制药株式会社 Fc区变体
PL2981822T3 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
CN105658666B (zh) * 2013-08-01 2021-07-27 鲁汶大学 抗garp蛋白及其用途
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
US10827945B2 (en) * 2014-03-10 2020-11-10 H. Lee. Moffitt Cancer Center And Research Institute, Inc. Radiologically identified tumor habitats
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
KR20170066515A (ko) * 2014-09-30 2017-06-14 우니베르지타이트 겐트 관절 질환의 치료 방법
TW201628649A (zh) 2014-10-09 2016-08-16 再生元醫藥公司 減少醫藥調配物中微可見顆粒之方法
WO2016069925A1 (en) * 2014-10-30 2016-05-06 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
WO2016073906A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
IL278014B2 (en) * 2014-12-19 2023-10-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
HK1245134A1 (zh) 2015-01-14 2018-08-24 The Brigham And Women's Hospital, Inc. 用抗lap单克隆抗体治疗癌症
WO2016125017A1 (en) * 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
SG10201907215QA (en) 2015-02-05 2019-09-27 Chugai Pharmaceutical Co Ltd Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US20180141972A1 (en) * 2015-05-15 2018-05-24 Agency For Science, Technology And Research Native protein purification technology
EP3324996A4 (en) * 2015-07-22 2019-04-17 Scholar Rock, Inc. GDF11 BINDING PROTEINS AND USES THEREOF
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
IL298067A (en) 2015-08-25 2023-01-01 Histide Ag Compounds for inducing tissue formation and their uses
PL3350220T3 (pl) * 2015-09-15 2022-01-03 Scholar Rock, Inc. Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowania
WO2017046229A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
KR20180050744A (ko) * 2015-09-17 2018-05-23 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
EP3998076A1 (en) * 2015-09-17 2022-05-18 Histide AG Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2017046226A2 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof.
WO2017088027A1 (en) * 2015-11-26 2017-06-01 Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research Inhibin analogs
CA3002422C (en) * 2015-12-18 2024-04-16 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
AU2017206069A1 (en) 2016-01-08 2018-07-19 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
BR112018068340A2 (pt) 2016-03-11 2019-01-15 Scholar Rock Inc imunoglobulinas de ligação ao tgfss1 e usos destas
CN109195990A (zh) 2016-03-30 2019-01-11 Musc研究发展基金会 通过靶向糖蛋白a重复优势蛋白(garp)治疗和诊断癌症以及单独或联合提供有效免疫疗法的方法
US10013527B2 (en) 2016-05-02 2018-07-03 Aranz Healthcare Limited Automatically assessing an anatomical surface feature and securely managing information related to the same
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
PT3368069T (pt) 2016-06-13 2020-11-11 Scholar Rock Inc Uso de inibidores da miostatina e terapias de combinação
AU2017294772B2 (en) 2016-07-14 2024-05-02 Scholar Rock, Inc. TGFB antibodies, methods, and uses
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
US11020686B2 (en) 2016-08-16 2021-06-01 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
EP3516063A4 (en) * 2016-09-20 2020-05-13 University of Pittsburgh- Of the Commonwealth System of Higher Education USE OF PROTEIN-BASED MEDICINES WITH AN ANCHOR DOMAIN FOR USE ON THE EYE SURFACE
KR20190127655A (ko) 2016-10-19 2019-11-13 프로디자인 소닉스, 인크. 음향학에 의한 친화성 세포 추출
BR112019006689A2 (pt) 2016-10-25 2019-06-25 Regeneron Pharma métodos e sistemas para análise de dados de cromatografia
WO2018081287A2 (en) * 2016-10-26 2018-05-03 The Children's Medical Center Corporation Methods and compositions for modulaton of transforming growth factor beta-regulated functions
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
US11116407B2 (en) 2016-11-17 2021-09-14 Aranz Healthcare Limited Anatomical surface assessment methods, devices and systems
EP3562840A1 (en) * 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
EP3366306B1 (en) * 2016-12-23 2021-09-29 Istanbul Üniversitesi Rektörlügü Use of some peptides in diagnosis and treatment of diabetes, obesity and metabolic diseases associated thereto
SI3565592T1 (sl) 2017-01-06 2023-05-31 Scholar Rock, Inc. Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina
PT3565592T (pt) 2017-01-06 2023-05-31 Scholar Rock Inc Tratamento de doenças metabólicas através da inibição da ativação da miostatina
KR20190098255A (ko) * 2017-01-06 2019-08-21 스칼러 락, 인크. 이소형-특이적, 콘텍스트-허용성 TGFβ1 억제제 및 그의 용도
TW202421659A (zh) 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
US10900786B2 (en) 2017-03-31 2021-01-26 International Business Machines Corporation Refining an ecological niche model
US11903723B2 (en) 2017-04-04 2024-02-20 Aranz Healthcare Limited Anatomical surface assessment methods, devices and systems
AU2018266784C9 (en) 2017-05-09 2024-10-03 Scholar Rock, Inc. LRRC33 inhibitors and use thereof
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
WO2019018632A1 (en) * 2017-07-19 2019-01-24 Musc Foundation For Research Development BLOCKING OF GARP CLEAVAGE AND METHODS OF USING THE SAME
US11957681B2 (en) * 2017-07-26 2024-04-16 Shorla Pharma Limited Liquid dosage forms of Imatinib
US12358992B2 (en) 2017-07-28 2025-07-15 Scholar Rock, Inc. LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
US12042538B2 (en) 2017-09-19 2024-07-23 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
EP3725092A4 (en) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. DRIVE AND CONTROL UNIT FOR ACOUSTIC CONVERTER
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
AU2019231307A1 (en) * 2018-03-09 2020-10-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Delivering biological drugs to tissues
CN112601538B (zh) 2018-05-09 2025-08-19 科乐斯疗法公司 激活素受体iia型变体及其使用方法
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
WO2020014473A1 (en) 2018-07-11 2020-01-16 Scholar Rock, Inc. TGFβ1 INHIBITORS AND USE THEREOF
LT3677278T (lt) 2018-07-11 2022-01-10 Scholar Rock, Inc. Izoformoms selektyvūs tgfbeta1 inhibitoriai ir jų panaudojimas
EP3820508A1 (en) 2018-07-11 2021-05-19 Scholar Rock, Inc. High-affinity, isoform-selective tgf?1 inhibitors and use thereof
JP2022504839A (ja) 2018-10-10 2022-01-13 ティロス・セラピューティクス・インコーポレイテッド 抗ｌａｐ抗体変異体及びその使用
TW202043267A (zh) 2019-01-30 2020-12-01 美商供石公司 TGFβ之LTBP複合物專一性抑制劑及其用途
WO2020234653A1 (en) 2019-05-20 2020-11-26 Aranz Healthcare Limited Automated or partially automated anatomical surface assessment methods, devices and systems
GB201908012D0 (en) * 2019-06-05 2019-07-17 Io Biotech Aps TGF-Beta vaccine
JP7350242B2 (ja) * 2019-07-19 2023-09-26 国立研究開発法人理化学研究所 ヒトＴＧＦ－βのＬＡＰ断片に対する抗体及びその利用
CN120022360A (zh) 2019-08-28 2025-05-23 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法
WO2021062171A1 (en) * 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating anemia of chronic disease
JP2022549506A (ja) * 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
CN111072764A (zh) * 2019-12-13 2020-04-28 东莞市东阳光生物药研发有限公司 一种重组人Activin A的制备方法
WO2021142427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. TGFβ INHIBITORS AND USE THEREOF
JP2023511255A (ja) 2020-01-11 2023-03-17 スカラー ロック インコーポレイテッド ＴＧＦ－β阻害剤及びその使用
CA3170142A1 (en) 2020-02-19 2021-08-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing tfgb antagonist prodrugs useful in the treatment of cancer and methods thereof
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2022271867A1 (en) 2021-06-23 2022-12-29 Scholar Rock, Inc. A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
GB202203269D0 (en) * 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies
US20250152670A1 (en) * 2022-04-28 2025-05-15 Wenzhou Prarucom Bio-Chemical Technology Co. Method for alleviating pulmonary fibrosis using epidermal growth factor
KR20250122524A (ko) 2022-12-22 2025-08-13 스칼러 락, 인크. 미오스타틴 활성화의 선택적이고 강력한 억제 항체
WO2025049960A1 (en) * 2023-08-30 2025-03-06 University Of Cincinnati Enhancing the production of anti-mullerian hormone through modification of its prodomain

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5001225A (en) 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JPH03180192A (ja) * 1989-12-07 1991-08-06 Kirin Brewery Co Ltd 遺伝子組換えによるヒトプロＴＧＦ―β１の製造
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
EP0553244B8 (en) 1990-10-05 2005-06-08 Celldex Therapeutics, Inc. Targeted immunostimulation with bispecific reagents
ATE160379T1 (de) 1990-10-29 1997-12-15 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5274166A (en) 1991-01-30 1993-12-28 Ihara Chemical Industry Co., Ltd. Dithiocarbamic acid salt, process for production thereof, and process for production of isothiocyanate using said dithiocarbamic acid salt
EP1471142B1 (en) 1991-04-10 2008-11-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DK0511011T3 (da) 1991-04-26 1997-03-10 Surface Active Ltd Nye antistoffer og fremgangsmåde til anvendelse heraf
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
JP3452946B2 (ja) 1992-02-19 2003-10-06 協和醗酵工業株式会社 抗ＴＧＦ−βマスキングプロテインモノクローナル抗体
AU3737893A (en) 1992-03-05 1993-10-05 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
US5951983A (en) 1993-03-05 1999-09-14 Universite Catholique De Louvain Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
WO1994021681A1 (en) 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
EP0711303B2 (en) 1993-07-30 2009-06-10 Affymax, Inc. Biotinylation of proteins
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
ATE435030T1 (de) 1994-03-29 2009-07-15 Renovo Ltd Heilung von wunden oder fibrotischen krankheiten unter verwendung von wenigstens einem agens gegen einen wachstumsfaktor
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5616561A (en) 1995-03-31 1997-04-01 Regents Of The University Of California TGF-β antagonists as mitigators of radiation-induced tissue damage
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5967979A (en) 1995-11-14 1999-10-19 Verg, Inc. Method and apparatus for photogrammetric assessment of biological tissue
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6407060B1 (en) 1996-03-22 2002-06-18 Curis, Inc. Method for enhancing functional recovery following central nervous system ischemia or trauma
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
CN100387621C (zh) 1997-04-14 2008-05-14 麦可麦脱股份公司 抗人抗原受体的新的生产方法及其用途
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
PT2045322E (pt) 1997-07-14 2015-10-16 Université de Liège Musculatura dupla em mamíferos
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
JP2001516766A (ja) 1997-09-19 2001-10-02 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 免疫反応の細胞内発現抗体仲介制御
AU765214B2 (en) 1998-05-06 2003-09-11 Metamorphix International, Inc. Methods for treating diabetes by inhibiting gdf-8
EP2128260A3 (en) 1998-10-07 2010-06-16 STRYKER CORPORATION (a Michigan corporation) Modified TGF-beta superfamily proteins
CA2359242C (en) 1999-01-21 2009-12-08 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
GB2344886B (en) 1999-03-10 2000-11-01 Medical Res Council Selection of intracellular immunoglobulins
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
WO2000066620A2 (en) 1999-04-30 2000-11-09 Curis, Inc. Morphogen-induced enhancement of fertility
US6784999B1 (en) 1999-05-17 2004-08-31 The Florida International University Board Of Trustees Surface plasmon resonance detection with high angular resolution and fast response time
EE200200025A (et) 1999-07-20 2003-04-15 Pharmexa A/S Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
US7358056B1 (en) 1999-08-30 2008-04-15 Signal Pharmaceuticals Methods for modulating signal transduction mediated by TGF-β and related proteins
IT1317922B1 (it) 2000-10-24 2003-07-15 S I S S A Scuola Internaz Supe Metodo per identificare in vivo epitopi intracellulari.
WO2002086096A2 (en) 2001-01-23 2002-10-31 University Of Rochester Medical Center Methods of producing or identifying intrabodies in eukaryotic cells
DE10108240B4 (de) 2001-02-21 2018-06-28 Leica Microsystems Cms Gmbh Verfahren zur Abbildung und Vermessung mikroskopischer dreidimensionaler Strukturen
EP1389071A2 (en) 2001-02-26 2004-02-18 Sabina Glozman Systems devices and methods for intrabody targeted delivery and reloading of therapeutic agents
GB0108165D0 (en) 2001-03-31 2001-05-23 Univ Manchester Intracellular analysis
CA2453662A1 (en) 2001-07-19 2003-01-30 Stefan Ewert Modification of human variable domains
JP2004538324A (ja) 2001-08-03 2004-12-24 メディカル リサーチ カウンシル 細胞内抗体
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
GB0201611D0 (en) 2002-01-24 2002-03-13 Grosveld Frank Transgenic animal
GB0226723D0 (en) 2002-11-15 2002-12-24 Medical Res Council Antibodies for in vitro use
WO2003077945A1 (en) 2002-03-14 2003-09-25 Medical Research Council Intracellular antibodies
GB0226727D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intrabodies
JP2006508638A (ja) 2002-05-22 2006-03-16 エスバテック・アーゲー 細胞内環境において向上した安定性を示す免疫グロブリンフレームワークおよびそれを同定する方法
EP1578928B1 (en) 2002-09-16 2010-03-17 The Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
WO2004046188A2 (en) 2002-11-15 2004-06-03 Medical Research Council Anti-activated ras antibodies
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
EP1482309A1 (en) 2003-05-07 2004-12-01 Institut Curie Means for detecting protein conformation and applications thereof
KR20060026860A (ko) 2003-06-02 2006-03-24 와이어쓰 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
US20050164909A1 (en) * 2003-07-16 2005-07-28 The Ohio State University Research Foundation Methods and reagents for treating inflammation and fibrosis
WO2005013915A2 (en) 2003-08-08 2005-02-17 The Regents Of The University Of California Novel indications for transforming growth factor-beta regulators
EP1674480A4 (en) * 2003-09-04 2007-06-20 Riken ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION
EP2441474B1 (en) 2003-10-17 2015-08-05 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
KR100500610B1 (ko) 2003-10-29 2005-07-11 한국전기연구원 형광 현미경 및 이를 사용한 관측 방법
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
KR20060120229A (ko) 2003-12-31 2006-11-24 쉐링-프라우 리미티드 중화 에피토프계 성장 증진 백신
EP1729793B1 (en) 2004-03-02 2015-07-22 Acceleron Pharma Inc. Alk7 and myostatin inhibitors for muscle wasting disorders
JP4695133B2 (ja) 2004-03-23 2011-06-08 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
US20100183695A1 (en) 2004-05-27 2010-07-22 John Knopf Cerberus/coco derivatives and uses thereof
US20060034831A1 (en) 2004-08-12 2006-02-16 Wyeth Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors
AU2005284793B2 (en) 2004-09-15 2011-07-07 The Trustees Of The University Of Pennsylvania Methods for the isolation and expansion of cord blood derived T regulatory cells
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
CA2582940A1 (en) 2004-09-30 2006-04-06 Orico Limited Myostatin isoform
JP2008518023A (ja) 2004-10-27 2008-05-29 メディミューン，インコーポレーテッド 同族抗原に対する親和性を改変することによる抗体特異性の調節
AU2005323087A1 (en) 2004-12-30 2006-07-13 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
ES2711213T3 (es) 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
JPWO2006106599A1 (ja) 2005-03-01 2008-09-11 国立大学法人京都大学 細胞外ドメインシェディングの異常亢進に起因する疾患の予防及び／又は治療のための医薬
WO2006103639A2 (en) 2005-03-31 2006-10-05 Case Western Reserve University Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals
ATE505489T1 (de) 2005-04-22 2011-04-15 Lilly Co Eli Tgf-beta-1-spezifische antikörper
AP2007004243A0 (en) 2005-04-25 2007-12-31 Pfizer Antibodies to myostatin
SI1915397T1 (sl) 2005-08-19 2015-05-29 Wyeth Llc Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
WO2007044411A2 (en) * 2005-10-06 2007-04-19 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8597646B2 (en) 2005-10-25 2013-12-03 The Johns Hopkins University Methods and compositons featuring TGF-beta antagonists for the treatment of marfan syndrome and associated disorders
WO2007109376A2 (en) 2006-03-23 2007-09-27 Novartis Ag Anti-tumor cell antigen antibody therapeutics
HRP20130320T1 (en) 2006-09-05 2013-05-31 Eli Lilly And Company Anti-myostatin antibodies
JP2008102117A (ja) 2006-09-21 2008-05-01 Fujifilm Corp 表面プラズモン増強蛍光センサおよび蛍光検出方法
ES2647472T3 (es) 2006-10-03 2017-12-21 Genzyme Corporation Anticuerpos contra TGF-BETA para uso en el tratamiento de lactantes con riesgo de desarrollar displasia broncopulmonar
WO2009018438A1 (en) 2007-07-31 2009-02-05 Cornell Research Foundation, Inc. Protein discovery using intracellular ribosome display
KR100988471B1 (ko) 2007-07-06 2010-10-18 전자부품연구원 실시간 세포 분석 장치 및 이를 이용한 세포의 대사 측정방법
WO2009014702A2 (en) 2007-07-25 2009-01-29 Board Of Regents, The University Of Texas System Cd74 for use in the treatment of cancer and liver toxicity
US20100291677A1 (en) 2007-08-24 2010-11-18 Keio University Reducer of immunosuppression by tumor cell and antitumor agent using the same
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
AU2009223115B2 (en) * 2008-03-14 2015-09-24 Humanzyme, Inc. Recombinant production of authentic human proteins using human cell expression systems
GB0809592D0 (en) 2008-05-27 2008-07-02 Imp Innovations Ltd Biomaterials
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20100009424A1 (en) 2008-07-14 2010-01-14 Natasha Forde Sonoporation systems and methods
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
US8669085B2 (en) 2009-02-05 2014-03-11 Ut-Battelle, Llc Transformation of gram positive bacteria by sonoporation
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
US8815779B2 (en) 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods
EP3260130B1 (en) 2009-11-03 2021-03-10 Acceleron Pharma Inc. Methods for treating fatty liver disease
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
WO2011102483A1 (ja) 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
SG10201506405YA (en) 2010-08-16 2015-10-29 Amgen Inc Polypeptides That Bind Myostatin, Compositions And Methods
JP6157352B2 (ja) 2010-10-08 2017-07-05 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ メディトープ（Ｍｅｄｉｔｏｐｅ）のためのモノクローナル抗体フレームワーク結合インターフェース、メディトープ送達系、およびその使用法
KR20140032394A (ko) 2011-03-30 2014-03-14 내셔날 유니버시티 코포레이션 유니버시티 오브 토야마 형질 세포 또는 형질아 세포의 선택 방법, 목적 항원 특이적인 항체의 제조 방법, 신규 단일 클론 항체
LT2714735T (lt) * 2011-06-03 2021-12-10 Xoma Technology Ltd. Tgf beta specifiniai antikūnai
WO2013016452A2 (en) 2011-07-25 2013-01-31 Vanderbilt University Cancer treatment using bmp inhibitor
JP6244301B2 (ja) 2011-08-18 2017-12-06 アフィニティ バイオサイエンス ピーティーワイ リミテッド 可溶性ポリペプチド
WO2013033420A1 (en) 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors
CN104039809A (zh) 2011-10-10 2014-09-10 希望之城公司 中间位和中间位结合抗体及其用途
WO2013074557A1 (en) 2011-11-14 2013-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
SI2794658T1 (sl) 2011-12-19 2017-05-31 Synimmune Gmbh Bispecifična molekula protitelesa
KR101704893B1 (ko) 2012-06-15 2017-02-08 화이자 인코포레이티드 Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
EP3165535B1 (en) 2012-08-22 2019-05-15 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
PL3564258T3 (pl) 2012-09-13 2021-10-25 Bristol-Myers Squibb Company Oparte na fibronektynie białka z domeną rusztowania, które wiążą się z miostatyną
SG11201503271XA (en) 2012-11-06 2015-05-28 Scholar Rock Inc Compositions and methods for modulating cell signaling
US20150328249A1 (en) 2012-12-11 2015-11-19 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Modulation of myofiber repair by anti-myostatin strategies and/or ppar gamma ligands, alone or in combination with stem cells, for the therapy of critical limb ischemia and other ischemic processes affecting the skeletal muscle
WO2014144573A2 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Multimerization technologies
PL2981822T3 (pl) * 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
CN105658666B (zh) 2013-08-01 2021-07-27 鲁汶大学 抗garp蛋白及其用途
EP2832747A1 (en) 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
EP3139957A4 (en) 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3215175A4 (en) * 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof

Also Published As

Publication number Publication date
AU2014262843B2 (en) 2017-06-22
AU2017203611C1 (en) 2021-12-23
JP2016521283A (ja) 2016-07-21
US20150337034A1 (en) 2015-11-26
SMT202100008T1 (it) 2021-03-15
JP2023156328A (ja) 2023-10-24
IL242193B (en) 2021-04-29
US9399676B2 (en) 2016-07-26
US11827698B2 (en) 2023-11-28
JP2017200915A (ja) 2017-11-09
IL301607A (en) 2023-05-01
HRP20201914T1 (hr) 2021-01-22
AU2014262843A1 (en) 2015-11-19
AU2017203611A1 (en) 2017-06-15
CA2911514A1 (en) 2014-11-13
US20190085067A1 (en) 2019-03-21
IL301607B1 (en) 2025-04-01
HUE052232T2 (hu) 2021-04-28
US9580500B2 (en) 2017-02-28
EP3816625B1 (en) 2025-09-17
US20150361175A1 (en) 2015-12-17
US20210284722A1 (en) 2021-09-16
US9758576B2 (en) 2017-09-12
US10981981B2 (en) 2021-04-20
US9573995B2 (en) 2017-02-21
SG10201800800YA (en) 2018-03-28
US12454570B2 (en) 2025-10-28
JP6796695B2 (ja) 2020-12-09
EP2981822A4 (en) 2017-02-15
US20170210798A1 (en) 2017-07-27
DK2981822T3 (da) 2020-12-07
AU2021204415A1 (en) 2021-07-29
US10597443B2 (en) 2020-03-24
US20180022798A1 (en) 2018-01-25
SI2981822T1 (sl) 2021-08-31
US20180016332A1 (en) 2018-01-18
PT2981822T (pt) 2020-12-07
PL2981822T4 (pl) 2021-07-12
ES2837042T3 (es) 2021-06-29
EP2981822B1 (en) 2020-09-02
AU2025201228A1 (en) 2025-05-08
JP2020062007A (ja) 2020-04-23
LT2981822T (lt) 2020-12-28
CY1123907T1 (el) 2022-03-24
IL319092A (en) 2025-04-01
US20160031980A1 (en) 2016-02-04
IL281549B2 (en) 2023-08-01
US20170190767A1 (en) 2017-07-06
IL301607B2 (en) 2025-08-01
AU2017203611B2 (en) 2019-03-07
AU2021204415B2 (en) 2024-11-21
US20160289318A1 (en) 2016-10-06
SG10201913751RA (en) 2020-03-30
US20200131259A1 (en) 2020-04-30
IL281549B1 (en) 2023-04-01
EP3816625A1 (en) 2021-05-05
EP2981822A2 (en) 2016-02-10
WO2014182676A3 (en) 2015-02-05
AU2019203834A1 (en) 2019-06-20
US20150361421A1 (en) 2015-12-17
WO2014182676A2 (en) 2014-11-13
US9758577B2 (en) 2017-09-12
US20240368261A1 (en) 2024-11-07
SG11201508681QA (en) 2015-11-27
JP2021050201A (ja) 2021-04-01
JP2025179097A (ja) 2025-12-09
IL281549A (en) 2021-05-31
RS61778B1 (sr) 2021-06-30

Similar Documents

Publication Publication Date Title
IL281549A (en) Compositions and methods for growth factor modulation
IL283660A (en) Compositions and methods for modulating apolipoprotein (a) expression
IL282202A (en) Compositions and methods for personalized neoplasia vaccines
HRP20180817T1 (hr) Sastavi i postupci za modulaciju farnesoid-x-receptora
IL241112B (en) Methods and compositions for modification of hla
PL2978419T3 (pl) Kompozycje do zwiększania żywotności komórek i metody ich stosowania
DK3444271T3 (da) Il-15- og il-15r-alfa-sushi-domænebaserede modulokiner
IL265876A (en) Preparations that include 15-ohepa and methods of using them
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
SG11201509136YA (en) Cenicriviroc compositions and methods of making and using the same
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
PL3030519T3 (pl) Trójpierścieniowe związki benzoksaborolu i ich zastosowania
PL3560558T3 (pl) Kompozycje nawozów oraz sposoby ich wytwarzania i stosowania
HRP20181291T1 (hr) Heterobicikloarilni inhibitori rorc2 i njihova upotreba
DK2956410T3 (da) Kompositsilicium- eller komposittinpartikler
KR101391404B9 (ko) 골신장기
LT3013855T (lt) Mutavusio viii faktoriaus kompozicijos ir metodai
PL2968346T3 (pl) Sposoby i kompozycje do modulacji cyklu gamma-glutamylowego
IL243288B (en) Enhancement of osteogenic potential of bone grafts
DK3068428T3 (da) Annexin-ii-variant-sammensætninger og fremgangsmåder
FR3007291B1 (fr) Composition cicatrisante et utlisation
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
TH1401007376A (th) ไดอะซาสไปโรไซโคลแอลเคนและอะซาสไปโรไซโคลแอลเคนชนิดใหม่
TH1401006308A (th) ส่วนควบคุมของพืชและการใช้ของมัน
UA27219S (uk) Форматор-вулканізатор 75" та 88"